Literature DB >> 10547539

Survival of patients with colorectal carcinoma: possible prognostic value of tissular carbohydrate antigen 19.9 determination.

C Morales-Gutiérrez1, I Vegh, F Colina, A Gómez-Cámara, J Ignacio Landa, D Ballesteros, P E Carreira, R Enríquez-De-Salamanca.   

Abstract

BACKGROUND: An important goal of serum tumor marker research is to provide a test for detecting cancer in early stages. Expression of carbohydrate antigen (CA) 19.9 has been described in various malignancies.
METHODS: The possible prognostic value measuring cytosol CA 19.9 expression in tumors was evaluated in a study of 63 colorectal carcinoma (CRC) patients who were followed for at least 2 years. CA 19.9 expression in cytosol was determined by enzyme-linked immunoadsorbant assay, and measurement of this protein achieved by quantitative assay.
RESULTS: Mean levels of cytosol CA 19.9 found in tumor samples were significantly higher than those in nontumoral areas in CRC patients (P<0.0005). Patients with more than 3 positive lymph nodes had a higher expression of the marker (P<0.05). Univariate and multivariate analyses revealed that cytosol CA 19.9 concentration was an independent prognostic variable for relapse. Furthermore, the probability of relapse increased 4.2 times for every increase in cytosol tumor marker of 5000 U/mg, and tumors located in the rectum had a probability of relapse 9.5 times greater.
CONCLUSIONS: Cystol CA 19.9 expression in CRC can be an independent prognostic factor for relapse. Patients with high levels of CA 19.9 have worse prognosis than those with lower values. Therefore, this group of patients should receive special management with regard to their follow-up and treatment. Moreover, quantitative cytosol tumor marker measurement is an easy and highly effective method for determining the prognoses of CRC patients. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547539

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Restaging of colorectal cancer and PET/CT.

Authors:  Alev Çınar; Esra Arzu Gençoğlu; Meliha Korkmaz
Journal:  Ulus Cerrahi Derg       Date:  2013-06-01

Review 2.  Effect of E-cadherin on Prognosis of Colorectal Cancer: A Meta-Analysis Update.

Authors:  Kaibin Chang; Lei Jiang; Yifeng Sun; He Li
Journal:  Mol Diagn Ther       Date:  2022-06-22       Impact factor: 4.476

3.  Free Fatty Acid is a Promising Biomarker in Triage Screening for Patients with Colorectal Cancer: A Case-Control Study.

Authors:  Bin Zhu; Junrong Zhang; Qingzhu Zheng; Binhua Dong; Meihua Wang; Jin Liu; Yingping Cao
Journal:  Cancer Manag Res       Date:  2021-05-10       Impact factor: 3.989

4.  Joint modelling of colorectal cancer recurrence and death after resection using multi-state model with cured fraction.

Authors:  Behnaz Alafchi; Ghodratollah Roshanaei; Leili Tapak; Mohammad Abbasi; Hossein Mahjub
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 5.  CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.

Authors:  Shicai Chen; Xinming Song; Zhihui Chen; Xinxin Li; Mingzhe Li; Haiying Liu; Jianchang Li
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

6.  Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.

Authors:  László Herszényi; Fabio Farinati; Romilda Cardin; Gábor István; László D Molnár; István Hritz; Massimo De Paoli; Mario Plebani; Zsolt Tulassay
Journal:  BMC Cancer       Date:  2008-07-10       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.